06 August 2013 | Regulatory | By BioSpectrum Bureau
Zoetis gets Chinese nod to make porcine reproductive and respiratory syndrome (HP PRRS) vaccine, Rui Lan An
Singapore: Zoetis, which is the animal health business of Pfizer, received approval by Chinese Ministry of Agriculture for Rui Lan An, a specialized vaccine to help control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS).
Rui Lan An, which will be launched later this month, is the first vaccine to emerge from Zoetis' joint venture in China that was established to develop and manufacture animal vaccines specifically designed to answer the needs of China's livestock producers. It will help China's pork producers meet increasing demand in China for quality, affordable pork.
Mr Stefan Weiskopf, executive VP and president, Asia Pacific region, Zoetis, said that, "Our innovation starts with our customers and an understanding of their everyday animal health challenges. Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China's pork industry."
"The vaccine represents our commitment to help assure a safe, sustainable food supply from healthy food production animals through global scientific expertise and local innovation. It is a key milestone for Zoetis' business in China," he added.